All News


All series


All All News

The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) to be used in combination with chemotherapy for first-line treatment of patients who have follicular lymphoma, according to Genentech, the manufacturer of the drug.

We’re moving into a new era of understanding with genetic abnormalities in colorectal cancer (CRC) as researchers continue to investigate tumor sidedness and the role of microsatellite instability (MSI) testing.